Why the study?
RSV disease is a major public health problem among infants younger than age 8 months, causing 100 to 300 deaths annually, with two new preventative treatments becoming available in 2023.
Nirsevimab and RSVPreF vaccine represent new available treatments as of 2023 for the prevention of RSV disease in infants.
Answers are grounded in this paper and cite their sources.
New RSV preventives may reduce infant deaths; leaves open real-world effectiveness and uptake data.
RSV disease is a major public health problem among infants younger than age 8 months, causing 100 to 300 deaths annually. In 2023, two new treatments, nirsevimab and RSVPreF vaccine, have become available to prevent RSV
No takes yet. Share an insight, caveat, or question.
Robert L. Barbieri (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: